Aksam Yassin1,2,3, Yousef Almehmadi1,2,3, Farid Saad2,4, Gheorghe Doros5, Louis Gooren6. 1. Institute of Urology and Andrology, Segeberger Kliniken, Norderstedt, Germany. 2. Gulf Medical University, Ajman, UAE. 3. Dresden International University, Dresden, Germany. 4. Global Medical Affairs Men's Healthcare, Bayer Pharma AG, Berlin, Germany. 5. Department of Epidemiology and Statistics, Boston University School of Public Health, Boston, MA, USA. 6. Department of Internal Medicine, Endocrine Section, VU medical Center, Amsterdam, The Netherlands.
Abstract
OBJECTIVE: In addition to primary and secondary ('classical') hypogonadism, hypogonadism occurring in middle-aged and elderly men has been recognized. There is evidence that restoring T levels to normal improves body weight, serum lipids and glucose levels. DESIGN: Observational registry study. PATIENTS: Two hundred and sixty-two hypogonadal, middle-aged and elderly, men received testosterone replacement treatment (TRT). After having been on TRT for a mean duration of 65·5 months, TRT was temporarily intermitted in 147 patients for a mean of 16·9 months (Group I) due to cost reimbursement issues and in seven men due to prostate cancer. All these men resumed TRT for a mean period of 14·5 months. Of the cohort, 115 men were treated continuously (designated as Group C). To compare on-treatment to off-treatment periods, three periods of equal duration were defined: pre-intermission (on TRT), during intermission (off TRT) and post-intermission (on TRT after resumption of TRT). For proper comparison, the same periods were analysed for those patients who continued TRT throughout (Group C). MEASUREMENTS: Variables of body weight, glucose metabolism, lipids, blood pressure and C-reactive protein (CRP). RESULTS: In Group C there was a continuous improvement of body weight, serum lipids, glucose, HbA1c , blood pressure and CRP. In Group I there was a similar initial improvement which was reversed upon intermission of T administration but which appeared again when T treatment was reinstated. CONCLUSIONS: Our observation indicates that T administration improves body weight and metabolic factors in men with hypogonadism but withdrawal of T reverses these beneficial effects to appear again when TRT is resumed.
OBJECTIVE: In addition to primary and secondary ('classical') hypogonadism, hypogonadism occurring in middle-aged and elderly men has been recognized. There is evidence that restoring T levels to normal improves body weight, serum lipids and glucose levels. DESIGN: Observational registry study. PATIENTS: Two hundred and sixty-two hypogonadal, middle-aged and elderly, men received testosterone replacement treatment (TRT). After having been on TRT for a mean duration of 65·5 months, TRT was temporarily intermitted in 147 patients for a mean of 16·9 months (Group I) due to cost reimbursement issues and in seven men due to prostate cancer. All these men resumed TRT for a mean period of 14·5 months. Of the cohort, 115 men were treated continuously (designated as Group C). To compare on-treatment to off-treatment periods, three periods of equal duration were defined: pre-intermission (on TRT), during intermission (off TRT) and post-intermission (on TRT after resumption of TRT). For proper comparison, the same periods were analysed for those patients who continued TRT throughout (Group C). MEASUREMENTS: Variables of body weight, glucose metabolism, lipids, blood pressure and C-reactive protein (CRP). RESULTS: In Group C there was a continuous improvement of body weight, serum lipids, glucose, HbA1c , blood pressure and CRP. In Group I there was a similar initial improvement which was reversed upon intermission of T administration but which appeared again when T treatment was reinstated. CONCLUSIONS: Our observation indicates that T administration improves body weight and metabolic factors in men with hypogonadism but withdrawal of T reverses these beneficial effects to appear again when TRT is resumed.
Authors: Monika Sarkar; Melissa Wellons; Marcelle I Cedars; Lisa VanWagner; Erica P Gunderson; Veeral Ajmera; Laura Torchen; David Siscovick; J Jeffrey Carr; James G Terry; Mary Rinella; Cora E Lewis; Norah Terrault Journal: Am J Gastroenterol Date: 2017-03-14 Impact factor: 10.864
Authors: Mustafa Alwani; Aksam Yassin; Raidh Talib; Ahmad Al-Qudimat; Omar Aboumarzouk; Raed M Al-Zoubi; Farid Saad; Karim S Haider; Abdulla Al Ansari Journal: Vasc Health Risk Manag Date: 2021-08-24
Authors: Raed M Al-Zoubi; Aksam A Yassin; Mustafa Alwani; Ahmad Al-Qudimat; Omar M Aboumarzouk; Ahmad Zarour; Abdulla Al Ansari Journal: Arab J Urol Date: 2021-08-08
Authors: Monika A Sarkar; Ayako Suzuki; Manal F Abdelmalek; Katherine P Yates; Laura A Wilson; Nathan M Bass; Ryan Gill; Marcelle Cedars; Norah Terrault Journal: Clin Gastroenterol Hepatol Date: 2020-10-01 Impact factor: 13.576